LumiraDX And BIVDA Speak On Challenges Of Driving Adoption Of Valuable Diagnostics
Executive Summary
Diagnostics such as c-reactive protein tests are more sensitive than ever before, but manufacturers are still struggling to place them in primary care and community settings where they can make huge differences.
You may also be interested in...
Is Osler Diagnostics The Next Theranos Or Can It Surprise Everyone?
Founded with a vision to change point-of-care diagnostics, Osler Diagnostics has raised nearly $200m to develop and commercialize a platform that promises to revolutionize diagnostics with just a drop of a patients’ blood.
Analyst Insight: Justifying A Price Target Following Poor SPAC Reception
In a discussion with Medtech Insight, analysts at Ladenburg Thalmann argued the case for their LumiraDX $14.75 price target.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.